Mercado Europeu de Tratamento da Sarcopenia – Tendências da Indústria e Previsão para 2030

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista  Comprar agora Comprar agora Consulte antes Comprar Consulte antes Relatório de amostra grátis Relatório de amostra grátis

Mercado Europeu de Tratamento da Sarcopenia – Tendências da Indústria e Previsão para 2030

  • Pharmaceutical
  • Publish Reports
  • Nov 2023
  • Europe
  • 350 Páginas
  • Número de tabelas: 291
  • Número de figuras: 43

Europe Sarcopenia Treatment Market

Tamanho do mercado em biliões de dólares

CAGR :  % Diagram

Diagram Período de previsão
2023 –2030
Diagram Tamanho do mercado (ano base )
US$ MILHÕES
Diagram Tamanho do mercado ( Ano de previsão)
USD 1,033,968.39
Diagram CAGR
%
Diagram Principais participantes do mercado
  • Manequim1
  • Manequim2
  • Manequim3
  • Manequim4
  • Manequim5

>Mercado europeu de tratamento da sarcopenia, por tipo de tratamento (medicamentos, vitaminas/ suplementos alimentares e outros), tipo (sarcopenia primária e sarcopenia secundária), estádios (pré-sarcopenia, sarcopenia e sarcopenia grave), via de administração (oral, injetável , e Outros), Género (Masculino e Feminino), Utilizador Final (Hospitais, Clínicas Especializadas, Assistência Domiciliária e Outros), Canal de Distribuição (Concurso Directo, Vendas a Retalho e Outros) - Tendências e Previsão do Sector para 2030.

Mercado europeu de tratamento da sarcopenia

Análise e dimensão do mercado de tratamento da sarcopenia na Europa

Os principais fatores que impulsionam o crescimento do mercado europeu de tratamento da sarcopenia são a crescente prevalência da sarcopenia. Além disso, a crescente consciencialização sobre a sarcopenia e o seu efeito prejudicial para a saúde é outro factor-chave para o crescimento do mercado. Os fatores de estilo de vida, como a má nutrição e o comportamento sedentário, também influenciam o mercado. No entanto, espera-se que a falta de diagnóstico padronizado e o elevado custo do tratamento e intervenção restrinjam o crescimento do mercado.

Mercado europeu de tratamento da sarcopeniaMercado europeu de tratamento da sarcopenia

A Data Bridge Market Research analisa que o mercado europeu de tratamento da sarcopenia deverá atingir o valor de 1.033.968,39 mil dólares até 2030, com um CAGR de 4,6% no período de previsão.

Este relatório de mercado também abrange análises de preços e avanços tecnológicos em profundidade.

Métrica de reporte

Detalhes

Período de previsão

2023 a 2030

Ano base

2022

Anos históricos

2021 (personalizável para 2015 - 2020)

Unidades Quantitativas

Receita em milhares de dólares, volumes em unidades, preços em dólares

Segmentos cobertos

Tipo de tratamento (medicamentos, suplementos vitamínicos/dietéticos e outros), tipo (sarcopenia primária e sarcopenia secundária), estadios (pré-sarcopenia, sarcopenia e sarcopenia grave), via de administração (oral, injetável e outros), género (Masculino e Feminino), Utilizador Final (Hospitais, Clínicas Especializadas, Assistência Domiciliária e Outros), Canal de Distribuição (Concurso Directo, Venda a Retalho e Outros)

Países abrangidos

Alemanha, França, Reino Unido, Itália, Espanha, Rússia, Turquia, Bélgica, Países Baixos, Suíça, Dinamarca, Noruega, Suécia, Polónia, Finlândia e resto da Europa

Participantes do mercado abrangidos

Abbott., Nestlé Health Science (uma subsidiária da Nestlé SA), Novartis AG, Sanofi, Haleon Group of Companies, BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, Wellona Pharma, The Vitamin Company India, Cura Pharma Índia Unip. Ltd., OPKO Health, Inc., NMD PHARMA A/S, Regeneron Pharmaceuticals Inc., Biophytis, ARMGO Pharma, Inc. E entre outros

Definição de mercado

O tratamento da sarcopenia refere-se ao cenário comercial relacionado com produtos e serviços destinados a prevenir, controlar ou abordar a sarcopenia – uma condição progressiva relacionada com a idade caracterizada pela perda de massa, força e função muscular esquelética, geralmente com início por volta dos 30 anos de idade e acelerando após os 60 anos.

A sarcopenia tem consequências significativas na saúde geral e na qualidade de vida de um indivíduo. Há um declínio correspondente na força e resistência muscular, tornando as tarefas diárias mais desafiantes e aumentando o risco de quedas e fraturas à medida que a massa muscular diminui. Além disso, a sarcopenia pode levar a alterações metabólicas, resistência à insulina e aumento da probabilidade de obesidade.

Dinâmica do mercado de tratamento da sarcopenia na Europa

Esta secção trata da compreensão dos impulsionadores do mercado, vantagens, oportunidades, restrições e desafios. Tudo isto é discutido em detalhe abaixo:

Motoristas

  • Aumento da prevalência da sarcopenia

A sarcopenia é uma condição médica caracterizada pela perda de massa, força e função muscular, principalmente em adultos mais velhos. Experimentam naturalmente uma perda gradual de massa e função muscular, o que os predispõe para a sarcopenia à medida que envelhecem. O número de indivíduos em risco de desenvolver sarcopenia aumenta constantemente com o envelhecimento da população mundial. Esta mudança demográfica impulsiona diretamente a procura de opções de tratamento da sarcopenia. A crescente prevalência da doença significa que mais indivíduos necessitam de diagnóstico e tratamento, criando um grupo maior de doentes para o mercado de tratamento da sarcopenia.

As pessoas estão a viver vidas mais longas com os avanços na saúde e na medicina. No entanto, à medida que os indivíduos envelhecem, são mais propensos a desenvolver sarcopenia. Esta maior esperança de vida contribui para a prevalência global da doença. Doenças crónicas como a diabetes, doenças cardiovasculares e cancro podem levar à perda muscular e contribuir para o desenvolvimento da sarcopenia. A crescente incidência destas condições tem um impacto direto no aumento da prevalência da sarcopenia.

Prevê-se que a procura de intervenções eficazes para prevenir ou gerir a sarcopenia aumente, promovendo a investigação, o desenvolvimento e a inovação no domínio do tratamento da sarcopenia à medida que a população mundial continua a envelhecer, o que deverá impulsionar o crescimento do mercado .

  • Crescente consciencialização sobre a sarcopenia e os seus efeitos prejudiciais para a saúde

A crescente consciencialização sobre a sarcopenia e os seus efeitos prejudiciais para a saúde é um desenvolvimento significativo no campo da saúde e do envelhecimento. Houve um aumento significativo de investigação e publicações relacionadas com a sarcopenia. Estudos científicos, revistas médicas e publicações forneceram aos profissionais de saúde informações valiosas sobre a prevalência, o diagnóstico e as consequências da doença. As escolas médicas e os programas de formação incorporaram a sarcopenia nos seus currículos. Isto garante que os profissionais de saúde, incluindo médicos, enfermeiros e fisioterapeutas, recebem educação sobre a sarcopenia, os seus factores de risco e estratégias de gestão.

Mercado europeu de tratamento da sarcopenia

Oportunidade

Iniciativas estratégicas dos principais players do mercado

The sarcopenia treatment market is witnessing substantial growth as it is a progressive age-related condition characterized by the loss of muscle mass, strength, and function. It is a significant health concern, particularly among the elderly population, as it can lead to decreased mobility, increased risk of falls and fractures, and a decline in overall quality of life due to which key market players are proactively taking strategic initiatives for product development. Thus, opening up opportunities for market expansion and advancement.

Strategic initiative includes collaborations and partnerships with research institutions, healthcare organizations, and academic centers. Market players can leverage their knowledge and resources to accelerate the development and commercialization of sarcopenia treatments by collaborating with experts in the field. Such collaborations facilitate knowledge exchange, access to patient populations for clinical trials, and the pooling of expertise to drive innovation in the market.

Restraint / Challenge

Lack of Standardized Diagnostics

The absence of standardized diagnostic criteria may result in delayed diagnosis or missed cases of sarcopenia. Healthcare professionals may not routinely screen for the condition, especially in adults, which can hinder early intervention and treatment initiation. Without a standardized diagnosis, healthcare providers may use different criteria and methods to identify sarcopenia. This inconsistency can lead to variations in the reported prevalence of sarcopenia and the number of diagnosed cases, making it challenging to assess the true market size and demand for treatments.

Sarcopenia is a multifaceted condition that can affect individuals differently based on factors such as age, gender, and comorbidities. Patient groups may be heterogeneous, making it challenging to conduct clinical trials and research to evaluate treatment efficacy accurately without standardized diagnostic criteria. Clinical trials for sarcopenia treatments may use different diagnostic criteria, making it challenging to compare the results of various studies. This lack of standardization can hinder the development and approval of new treatments by regulatory agencies.

Recent Developments

  • In February 2023, Nestlé Health Science announced that they entered into a research collaboration with EraCal Therapeutics, to identify novel nutraceuticals relevant to controlling food intake. This will increase the company's product portfolio and overall revenue.
  • In November 2022, Abbott announced that it has been awarded by the Consumer Technology Association (CTA) with three CES 2023 innovation awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide.

Europe Sarcopenia Treatment Market Scope

The Europe sarcopenia treatment market is segmented into seven notable segments such as treatment type, type, stages, route of administration, gender, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

  • Vitamin/Dietary Supplements
  • Medications
  • Others

On the basis of treatment type, the market is segmented into medications, vitamin/dietary supplements, and others.

Type

  • Primary Sarcopenia
  • Secondary Sarcopenia

On the basis of type the market is segmented into primary sarcopenia and secondary sarcopenia.

Stages

  • Pre-Sarcopenia
  • Sarcopenia
  • Severe Sarcopenia

On the basis of stages, the market is segmented into pre-sarcopenia, sarcopenia, and severe sarcopenia.

Route of Administration

  • Oral
  • Injectable
  • Others

On the basis of route of administration the market is segmented into oral, injectable, and others.

Gender

  • Male
  • Female

On the basis of gender the market is segmented into male and female.

End User

  • Hospitals
  • Speciality Clinics
  • Home Healthcare
  • Others

On the basis of end user, the market is segmented into hospitals, specialty clinics, home healthcare, and others.

Distribution Channel

  • Direct Tender
  • Retail Sales
  • Others

On the basis of distribution channel the market is segmented into direct tender, retail sales, and others.

Mercado europeu de tratamento da sarcopenia

Europe Sarcopenia Treatment Market Regional Analysis/Insights

The Europe sarcopenia treatment market is analyzed and market size insights and trends are provided by country, treatment type, type, stages, route of administration, gender, end user, and distribution channel.

The countries covered in this market report are Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, and Rest of Europe.

Germany is expected to dominate the Europe sarcopenia treatment market owing to the higher level of investments by various manufacturers and increasing demand for pharmaceutical products manufacturing in the region.

The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Sarcopenia Treatment Market Share Analysis

O cenário competitivo do mercado europeu de tratamento da sarcopenia fornece detalhes do concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, novas iniciativas de mercado, presença regional, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa, lançamento de produtos, largura e amplitude do produto e domínio de aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas em relação ao mercado.

Alguns dos principais players do mercado que operam no mercado europeu de tratamento da sarcopenia são a Abbott., Nestlé Health Science (uma subsidiária da Nestlé SA), Novartis AG, Sanofi, Haleon Group of Companies., BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, Wellona Pharma, The Vitamin Company India, Healing Pharma India Unip. Lda. e entre outros.


SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE EUROPE SARCOPENIA TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE

2.8 MARKET END USER COVERAGE GRID

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES MODEL

4.3 CURRENT STATUS OF EMERGING DRUGS FOR SARCOPENIA TREATMENT

5 EUROPE SARCOPENIA TREATMENT MARKET: REGULATIONS

5.1 REGULATIONS IN U.S.

5.2 REGULATIONS IN EUROPE

5.3 REGULATIONS IN AUSTRALIA

5.4 REGULATIONS IN SOUTH AFRICA

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF SARCOPENIA

6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH

6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR

6.2 RESTRAINTS

6.2.1 LACK OF STANDARDIZED DIAGNOSIS

6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS

6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

6.4 CHALLENGES

6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT

6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL

7 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE

7.1 OVERVIEW

7.2 VITAMIN/DIETARY SUPPLEMENTS

7.2.1 VITAMIN SUPPLEMENTS

7.2.2 PROTEIN SUPPLEMENTS

7.2.3 FATTY ACID SUPPLEMENTS

7.2.4 CREATINE

7.2.5 WHEY PROTEINS

7.2.6 L-CARNITINE

7.2.7 SOY

7.2.8 BETA-ALANINE

7.2.9 OSTARINE

7.2.10 COLLAGEN PEPTIDES

7.2.11 LIGANDROL

7.2.12 BRANCH-CHAIN AMINO ACIDS

7.2.13 HYDROXYMETHYLBUTYRATE (HMB)

7.2.14 MEDIUM CHAIN TRIGLYCERIDES

7.2.15 OTHERS

7.3 MEDICATIONS

7.3.1 OFF LABEL DRUGS

7.3.2 EMERGING DRUGS

7.3.2.1 ACE INHIBITORS

7.3.2.2 APPETITE STIMULANTS

7.3.2.3 ORAL ANTIDIABETIC DRUGS

7.3.2.4 OTHERS

7.4 OTHERS

8 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE

8.1 OVERVIEW

8.2 PRIMARY SARCOPENIA

8.2.1 VITAMIN/DIETARY SUPPLEMENTS

8.2.2 MEDICATIONS

8.2.3 OTHERS

8.3 SECONDARY SARCOPENIA

8.3.1 VITAMIN/DIETARY SUPPLEMENTS

8.3.2 MEDICATIONS

8.3.3 OTHERS

9 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES

9.1 OVERVIEW

9.2 PRE-SARCOPENIA

9.3 SARCOPENIA

9.4 SEVERE SARCOPENIA

10 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 ORAL

10.3 INJECTABLES

10.4 OTHERS

11 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER

11.1 OVERVIEW

11.2 MALE

11.3 FEMALE

12 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.2.1 PUBLIC

12.2.2 PRIVATE

12.3 SPECIALTY CLINICS

12.4 HOME HEALTHCARE

12.5 OTHERS

13 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 RETAIL SALES

13.3.1 HOSPITAL PHARMACIES

13.3.2 ONLINE PHARMACIES

13.3.3 OTHERS

13.4 OTHERS

14 EUROPE SARCOPENIA TREATMENT MARKET, BY REGION

14.1 EUROPE

14.1.1 GERMANY

14.1.2 FRANCE

14.1.3 U.K.

14.1.4 ITALY

14.1.5 SPAIN

14.1.6 RUSSIA

14.1.7 TURKEY

14.1.8 BELGIUM

14.1.9 NETHERLANDS

14.1.10 SWITZERLAND

14.1.11 DENMARK

14.1.12 NORWAY

14.1.13 SWEDEN

14.1.14 POLAND

14.1.15 FINLAND

14.1.16 REST OF EUROPE

15 EUROPE SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: EUROPE

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 ABBOTT

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.2 NESTLÉ HEALTH SCIENCE (A SUBSIDIARY OF NESTLÉ S.A.)

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENT

17.3 NOVARTIS AG

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 PIPELINE PORTFOLIO

17.3.6 RECENT DEVELOPMENT

17.4 SANOFI

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENT

17.5 HALEON GROUP OF COMPANIES.

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENT

17.6 ASTAREAL CO., LTD.

17.6.1 COMPANY SNAPSHOT

17.6.2 PRODUCT PORTFOLIO

17.6.3 RECENT DEVELOPMENT

17.7 BASF SE

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENT

17.8 BIOGEN SA

17.8.1 COMPANY SNAPSHOT

17.8.2 PRODUCT PORTFOLIO

17.8.3 RECENT DEVELOPMENT

17.9 BIOTHRIVE SCIENCES

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENT

17.1 DSM

17.10.1 COMPANY SNAPSHOT

17.10.2 REVENUE ANALYSIS

17.10.3 PRODUCT PORTFOLIO

17.10.4 RECENT DEVELOPMENT

17.11 FERMENTA BIOTECH LIMITED

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENT

17.12 HEALING PHARMA INDIA PVT. LTD.

17.12.1 COMPANY SNAPSHOT

17.12.2 PRODUCT PORTFOLIO

17.12.3 RECENT DEVELOPMENT

17.13 METAGENICS

17.13.1 COMPANY SNAPSHOT

17.13.2 PRODUCT PORTFOLIO

17.13.3 RECENT DEVELOPMENT

17.14 THE VITAMIN COMPANY INDIA

17.14.1 COMPANY SNAPSHOT

17.14.2 PRODUCT PORTFOLIO

17.14.3 RECENT DEVELOPMENT

17.15 WELLONA PHARMA

17.15.1 COMPANY SNAPSHOT

17.15.2 PRODUCT PORTFOLIO

17.15.3 RECENT DEVELOPMENT

17.16 ARMGO PHARMA, INC.

17.16.1 COMPANY SNAPSHOT

17.16.2 PIPELINE PORTFOLIO

17.16.3 RECENT DEVELOPMENT

17.17 BIOPHYTIS

17.17.1 COMPANY SNAPSHOT

17.17.2 PIPELINE PORTFOLIO

17.17.3 RECENT DEVELOPMENT

17.18 DYSTROGEN THERAPEUTICS CORP

17.18.1 COMPANY SNAPSHOT

17.18.2 PIPELINE PORTFOLIO

17.18.3 RECENT DEVELOPMENT

17.19 IMMUNOFORGE INC.

17.19.1 COMPANY SNAPSHOT

17.19.2 PIPELINE PORTFOLIO

17.19.3 RECENT DEVELOPMENT

17.2 MYMD PHARMACEUTICALS

17.20.1 COMPANY SNAPSHOT

17.20.2 PIPELINE PORTFOLIO

17.20.3 RECENT DEVELOPMENT

17.21 NMD PHARMA A/S

17.21.1 COMPANY SNAPSHOT

17.21.2 PIPELINE PORTFOLIO

17.21.3 RECENT DEVELOPMENT

17.22 ONCOCROSS CO., LTD.

17.22.1 COMPANY SNAPSHOT

17.22.2 PIPELINE PORTFOLIO

17.22.3 RECENT DEVELOPMENT

17.23 OPKO HEALTH, INC.

17.23.1 COMPANY SNAPSHOT

17.23.2 REVENUE ANALYSIS

17.23.3 PIPELINE PORTFOLIO

17.23.4 RECENT DEVELOPMENT

17.24 REGENERON PHARMACEUTICALS INC.

17.24.1 COMPANY SNAPSHOT

17.24.2 REVENUE ANALYSIS

17.24.3 PIPELINE PORTFOLIO

17.24.4 RECENT DEVELOPMENT

17.25 REJUVENATE BIOMED NV

17.25.1 COMPANY SNAPSHOT

17.25.2 PIPELINE PORTFOLIO

17.25.3 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

Lista de Tabela

TABLE 1 CURRENT STATUS OF THE DEVELOPMENT OF DRUG FOR SARCOPENIA TREATMENT

TABLE 2 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 3 EUROPE VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 4 EUROPE VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 5 EUROPE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 6 EUROPE MEDICATINONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 7 EUROPE OFF-LABLE DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 8 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 9 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 10 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 11 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 12 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 13 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 14 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 15 EUROPE PRE-SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 16 EUROPE SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 17 EUROPE SEVERE SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 18 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 19 EUROPE ORAL IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 20 EUROPE INJECTABLES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 22 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 23 EUROPE MALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 24 EUROPE FEMALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 25 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 26 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 27 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 28 EUROPE SPECIALTY CLINICS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 29 EUROPE HOME HEALTHCARE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 30 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 31 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 32 EUROPE DIRECT TENDER IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 33 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 34 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 35 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 36 EUROPE SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 37 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 38 EUROPE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 39 EUROPE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 40 EUROPE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 41 EUROPE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 42 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 43 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 44 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 45 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 46 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 47 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 48 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 49 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 50 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 51 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 52 GERMANY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 53 GERMANY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 54 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 55 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 56 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 57 GERMANY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 58 GERMANY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 59 GERMANY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 60 GERMANY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 61 GERMANY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 62 GERMANY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 63 GERMANY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 64 GERMANY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 65 GERMANY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 66 GERMANY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 67 GERMANY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 68 FRANCE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 69 FRANCE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 70 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 71 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 72 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 73 FRANCE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 74 FRANCE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 75 FRANCE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 76 FRANCE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 77 FRANCE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 78 FRANCE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 79 FRANCE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 80 FRANCE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 81 FRANCE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 82 FRANCE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 83 FRANCE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 84 U.K. SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 85 U.K. MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 86 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 87 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 88 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 89 U.K. VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 90 U.K. SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 91 U.K. PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 92 U.K. SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 93 U.K. SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 94 U.K. SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 95 U.K. SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 96 U.K. SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 97 U.K. HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 98 U.K. SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 99 U.K. RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 100 ITALY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 101 ITALY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 102 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 103 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 104 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 105 ITALY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 106 ITALY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 107 ITALY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 108 ITALY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 109 ITALY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 110 ITALY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 111 ITALY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 112 ITALY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 113 ITALY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 114 ITALY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 115 ITALY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 116 SPAIN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 117 SPAIN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 118 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 119 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 120 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 121 SPAIN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 122 SPAIN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 123 SPAIN PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 124 SPAIN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 125 SPAIN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 126 SPAIN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 127 SPAIN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 128 SPAIN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 129 SPAIN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 130 SPAIN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 131 SPAIN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 132 RUSSIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 133 RUSSIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 134 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 135 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 136 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 137 RUSSIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 138 RUSSIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 139 RUSSIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 140 RUSSIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 141 RUSSIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 142 RUSSIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 143 RUSSIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 144 RUSSIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 145 RUSSIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 146 RUSSIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 147 RUSSIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 148 TURKEY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 149 TURKEY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 150 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 151 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 152 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 153 TURKEY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 154 TURKEY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 155 TURKEY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 156 TURKEY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 157 TURKEY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 158 TURKEY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 159 TURKEY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 160 TURKEY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 161 TURKEY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 162 TURKEY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 163 TURKEY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 164 BELGIUM SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 165 BELGIUM MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 166 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 167 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 168 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 169 BELGIUM VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 170 BELGIUM SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 171 BELGIUM PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 172 BELGIUM SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 173 BELGIUM SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 174 BELGIUM SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 175 BELGIUM SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 176 BELGIUM SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 177 BELGIUM HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 178 BELGIUM SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 179 BELGIUM RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 180 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 181 NETHERLANDS MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 182 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 183 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 184 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 185 NETHERLANDS VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 186 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 187 NETHERLANDS PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 188 NETHERLANDS SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 189 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 190 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 191 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 192 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 193 NETHERLANDS HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 194 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 195 NETHERLANDS RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 196 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 197 SWIZTERLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 198 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 199 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 200 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 201 SWIZTERLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 202 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 203 SWIZTERLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 204 SWIZTERLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 205 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 206 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 207 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 208 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 209 SWIZTERLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 210 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 211 SWIZTERLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 212 DENMARK SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 213 DENMARK MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 214 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 215 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 216 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 217 DENMARK VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 218 DENMARK SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 219 DENMARK PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 220 DENMARK SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 221 DENMARK SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 222 DENMARK SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 223 DENMARK SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 224 DENMARK SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 225 DENMARK HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 226 DENMARK SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 227 DENMARK RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 228 NORWAY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 229 NORWAY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 230 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 231 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 232 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 233 NORWAY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 234 NORWAY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 235 NORWAY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 236 NORWAY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 237 NORWAY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 238 NORWAY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 239 NORWAY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 240 NORWAY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 241 NORWAY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 242 NORWAY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 243 NORWAY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 244 SWEDEN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 245 SWEDEN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 246 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 247 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 248 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 249 SWEDEN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 250 SWEDEN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 251 SWEDEN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 252 SWEDEN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 253 SWEDEN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 254 SWEDEN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 255 SWEDEN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 256 SWEDEN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 257 SWEDEN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 258 SWEDEN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 259 POLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 260 POLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 261 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 262 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 263 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 264 POLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 265 POLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 266 POLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 267 POLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 268 POLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 269 POLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 270 POLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 271 POLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 272 POLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 273 POLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 274 POLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 275 FINLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 276 FINLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 277 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 278 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 279 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 280 FINLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 281 FINLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 282 FINLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 283 FINLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 284 FINLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 285 FINLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 286 FINLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 287 FINLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 288 FINLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 289 FINLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 290 FINLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 291 REST OF EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

Lista de Figura

FIGURE 1 EUROPE SARCOPENIA TREATMENT MARKET: SEGMENTATION

FIGURE 2 EUROPE SARCOPENIA TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE SARCOPENIA TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 EUROPE SARCOPENIA TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE SARCOPENIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE SARCOPENIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE SARCOPENIA TREATMENT MARKET: MARKET END USERS COVERAGE GRID

FIGURE 8 EUROPE SARCOPENIA TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE SARCOPENIA TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE SARCOPENIA TREATMENT MARKET: SEGMENTATION

FIGURE 11 THE RISING PREVALENCE OF SARCOPENIA AND GROWING AWARENESS OF SARCOEPNIA AND ITS DETRIMENTAL EFFECT ON HEALTH ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE SARCOPENIA TREATMENT MARKET FROM 2023 TO 2030

FIGURE 12 VITAMIN/DIETARY SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PRECLINICAL MARKET IN 2023 AND 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE SARCOPENIA TREATMENT MARKET

FIGURE 14 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2022

FIGURE 15 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)

FIGURE 16 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2023-2030)

FIGURE 17 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 18 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, 2022

FIGURE 19 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND)

FIGURE 20 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 21 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 22 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, 2022

FIGURE 23 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, 2023-2030 (USD THOUSAND)

FIGURE 24 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, CAGR (2023-2030)

FIGURE 25 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, LIFELINE CURVE

FIGURE 26 EUROPE SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 27 EUROPE SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030)

FIGURE 28 EUROPE SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030)

FIGURE 29 EUROPE SARCOPENIA TREATMENT MARKET: LIFELINE CURVE

FIGURE 30 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, 2022

FIGURE 31 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, 2023-2030 (USD THOUSAND)

FIGURE 32 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, CAGR (2023-2030)

FIGURE 33 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 34 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, 2022

FIGURE 35 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 36 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, CAGR (2023-2030)

FIGURE 37 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 39 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 40 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 41 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 42 EUROPE SARCOPENIA TREATMENT MARKET: SNAPSHOT (2022)

FIGURE 43 EUROPE SARCOPENIA TREATMENT MARKETSTRUCTURAL HEALTH MONITORING MARKET: COMPANY SHARE 2022 (%)

View Detailed Information Right Arrow

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

The Europe sarcopenia treatment market size will be worth USD 1,033,968.39 thousand by 2030.
The growth rate of the Europe sarcopenia treatment market is 4.6% by the forecasted time period.
The rising prevalence of sarcopenia & growing awareness of sarcopenia and its detrimental effects on health are the growth drivers of the Europe sarcopenia treatment market.
Treatment type, type, stages, route of administration, gender, end user, and distribution channel are the factors on which the Europe sarcopenia treatment market research is based.
Major companies in the Europe sarcopenia treatment market are Abbott., Nestlé Health Science (A subsidary of Nestlé S.A.), Novartis AG, Sanofi, Haleon Group of Companies., BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, Wellona Pharma, The Vitamin Company India & Healing Pharma India Pvt. Ltd.